

October 8, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

SymBio Announces Initiation of Compassionate Use Program for Brincidofovir

**Investigational BCV now accessible to patients with adenovirus infection
following hematopoietic stem cell transplantation who are unable to
participate in clinical trials**

Tokyo, Japan, October 8, 2026 – SymBio Pharmaceuticals Limited (“SymBio” or the “Company”) today announced that it will initiate a Compassionate Use Program (“CUP”) for brincidofovir (“BCV”) for patients with adenovirus infection following hematopoietic stem cell transplantation. The program will begin today.

Adenovirus infection following hematopoietic stem cell transplantation can become extremely severe in immunocompromised patients and may lead to fatal outcomes. However, for a substantial number of patients, existing treatments lack sufficient efficacy or must be discontinued due to adverse effects.

SymBio is currently accelerating the global Phase 3 clinical trial of BCV in the United States and Europe. We have received numerous requests from patients and their families seeking access to BCV who do not meet the clinical trial eligibility criteria, have no alternative treatment options, and are facing life-threatening conditions. As a company whose mission is to address unmet medical needs, SymBio has made the decision, on humanitarian grounds, to provide BCV, which is currently unapproved, at the earliest possible opportunity and subject to strict eligibility criteria.

SymBio's CUP policy is publicly accessible on our website at [\[Link\]](#)

Statement from Minori Rosales, Corporate Vice President and Chief Medical Officer:
“Given that BCV is an unapproved drug, we will implement the Compassionate Use program initiated today with due caution. At the same time, we will continue to advance the clinical trial steadily as a company united in its efforts to make BCV available to patients as soon as possible.”

The Company does not expect this matter to have a material impact on its consolidated financial results for the fiscal year ending December 2026.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125

Notes

Note 1: Compassionate Use Program

Also referred to as “Expanded Access,” a Compassionate Use Program is a mechanism that permits the use of an unapproved drug under limited circumstances, such as when no alternative treatment is available. These programs primarily seek to provide relief to patients facing life-threatening or severely debilitating diseases. Such programs are recognized under the regulatory frameworks of the United States, the European Union, and other jurisdictions.

Note 2: Clinical Trial for Adenovirus Infection Following Hematopoietic Stem Cell Transplantation

The global Phase 3 clinical trial is currently being conducted in the United States and Europe. As of end September, 2026, 35 patients had been enrolled. The enrollment targets are 69 patients by the end of 2026 and 180 patients by the end of 2027.

About SymBio Pharmaceuticals: BCV Business Strategy Centered on Three Therapeutic Areas

Since obtaining the global license for brincidofovir (“BCV”) in September 2019, SymBio Pharmaceuticals has conducted joint research with world-leading research institutions in three therapeutic areas—double-stranded DNA virus infections, solid tumors, and neurodegenerative diseases—with the aim of unlocking BCV’s potential in each area.

SymBio is concentrating its management resources on the development of BCV, primarily for adenovirus infection following hematopoietic stem cell transplantation, progressive multifocal leukoencephalopathy (“PML”), glioblastoma, head and neck cancer, and EBV-associated gastric cancer. Through global business development, SymBio aims to maximize the business value of BCV.